Pharmaceutical manufacturer operating across endocrine, neurology, and oncology markets in China
Eli Lilly China operates a 1,000+ person manufacturing and commercial organization in Shanghai, selling established brands (Prozac, Zyprexa, Cymbalta, Humalog, Cialis, and others) across endocrine, CNS, and oncology. The tech stack is lightweight—Office, Python, pandas, and manufacturing systems (PLC/HMI)—reflecting a pharma ops profile: hiring is sparse but accelerating, tilted heavily toward interns, and scattered across finance, data, engineering, manufacturing, and research. Active projects cluster around GMP/sterilization validation and equipment reliability, while stated pain points center on regulatory IT compliance and system maintenance, typical of highly regulated manufacturing environments.
Eli Lilly China is the China subsidiary of a publicly traded global pharmaceutical manufacturer founded in 1876. The company maintains a Shanghai headquarters and employs over 1,000 people across commercial, manufacturing, and support functions. Its portfolio includes branded therapeutics in endocrine management, central nervous system disorders, and oncology. Operations span drug manufacturing (sterilization validation, clean-room qualification), commercial distribution, and internal IT/financial systems supporting pharma-grade compliance. The organization adheres to GMP and regulatory standards across IT infrastructure and manufacturing processes.
The company operates with 1,001–5,000 employees, headquartered in Shanghai.
Primary tools include Microsoft Office (Word, Excel, PowerPoint, Outlook), Python, pandas, VBA, and manufacturing systems (PLC/HMI). The stack reflects pharmaceutical operations and financial/data automation.
Other companies in the same industry, closest in size